Annual FCF
-$49.02 M
+$7.81 M+13.75%
December 31, 2023
Summary
- As of February 28, 2025, SLN annual free cash flow is -$49.02 million, with the most recent change of +$7.81 million (+13.75%) on December 31, 2023.
- During the last 3 years, SLN annual FCF has fallen by -$34.53 million (-238.30%).
- SLN annual FCF is now -751.16% below its all-time high of $7.53 million, reached on December 31, 2021.
Performance
SLN Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$26.13 M
-$20.02 M-327.79%
September 30, 2024
Summary
- As of February 28, 2025, SLN quarterly free cash flow is -$26.13 million, with the most recent change of -$20.02 million (-327.79%) on September 30, 2024.
- Over the past year, SLN quarterly FCF has dropped by -$11.97 million (-84.50%).
- SLN quarterly FCF is now -173.53% below its all-time high of $35.54 million, reached on June 30, 2021.
Performance
SLN Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$55.91 M
-$19.61 M-54.01%
September 30, 2024
Summary
- As of February 28, 2025, SLN TTM free cash flow is -$55.91 million, with the most recent change of -$19.61 million (-54.01%) on September 30, 2024.
- Over the past year, SLN TTM FCF has dropped by -$6.89 million (-14.05%).
- SLN TTM FCF is now -396.61% below its all-time high of $18.85 million, reached on June 30, 2021.
Performance
SLN TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
SLN Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.8% | -84.5% | -14.1% |
| 3 y3 years | -238.3% | -37.9% | +1.6% |
| 5 y5 years | -116.8% | -37.9% | +1.6% |
SLN Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -751.2% | +13.8% | -584.9% | at low | -842.7% | +1.6% |
| 5 y | 5-year | -751.2% | +13.8% | -173.5% | at low | -396.6% | +1.6% |
| alltime | all time | -751.2% | +13.8% | -173.5% | at low | -396.6% | +1.6% |
Silence Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$26.13 M(+327.8%) | -$55.91 M(+54.0%) |
| Jun 2024 | - | -$6.11 M(-35.7%) | -$36.30 M(-26.2%) |
| Mar 2024 | - | -$9.51 M(-32.9%) | -$49.18 M(+0.3%) |
| Dec 2023 | -$49.02 M(-13.7%) | -$14.16 M(+117.1%) | -$49.02 M(-8.9%) |
| Sep 2023 | - | -$6.52 M(-65.6%) | -$53.81 M(-4.9%) |
| Jun 2023 | - | -$18.99 M(+103.2%) | -$56.59 M(+20.7%) |
| Mar 2023 | - | -$9.35 M(-50.7%) | -$46.89 M(-17.5%) |
| Dec 2022 | -$56.83 M(-855.0%) | -$18.96 M(+103.8%) | -$56.83 M(+36.3%) |
| Sep 2022 | - | -$9.30 M(+0.1%) | -$41.69 M(+4.5%) |
| Jun 2022 | - | -$9.29 M(-51.8%) | -$39.90 M(-909.4%) |
| Mar 2022 | - | -$19.29 M(+405.6%) | $4.93 M(-34.5%) |
| Dec 2021 | $7.53 M(-152.0%) | -$3.82 M(-49.2%) | $7.53 M(-33.6%) |
| Sep 2021 | - | -$7.51 M(-121.1%) | $11.34 M(-39.8%) |
| Jun 2021 | - | $35.54 M(-312.9%) | $18.85 M(-212.9%) |
| Mar 2021 | - | -$16.69 M | -$16.69 M |
| Dec 2020 | -$14.49 M(-760.6%) | - | - |
| Dec 2019 | $2.19 M(-109.7%) | - | - |
| Dec 2018 | -$22.61 M(+79.2%) | - | - |
| Dec 2017 | -$12.62 M(-12.2%) | - | - |
| Dec 2016 | -$14.37 M(+3.2%) | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2015 | -$13.91 M(-13.8%) | - | - |
| Dec 2014 | -$16.14 M(+49.7%) | - | - |
| Dec 2013 | -$10.79 M(+34.0%) | - | - |
| Dec 2012 | -$8.05 M(-6.6%) | - | - |
| Dec 2011 | -$8.61 M(-48.5%) | - | - |
| Dec 2010 | -$16.72 M(+119.0%) | - | - |
| Dec 2009 | -$7.63 M(-43.1%) | - | - |
| Dec 2008 | -$13.41 M(+53.6%) | - | - |
| Dec 2007 | -$8.73 M(+13.9%) | - | - |
| Dec 2006 | -$7.67 M(+47.1%) | - | - |
| Dec 2005 | -$5.21 M(+20.2%) | - | - |
| Dec 2004 | -$4.34 M(+28.3%) | - | - |
| Dec 2003 | -$3.38 M(+17.4%) | - | - |
| Dec 2002 | -$2.88 M(-12.7%) | - | - |
| Dec 2001 | -$3.30 M(-26.9%) | - | - |
| Dec 2000 | -$4.51 M(+145.0%) | - | - |
| Dec 1999 | -$1.84 M(-38.7%) | - | - |
| Dec 1998 | -$3.00 M(+20.1%) | - | - |
| Dec 1997 | -$2.50 M(+94.2%) | - | - |
| Dec 1996 | -$1.29 M(+6.9%) | - | - |
| Dec 1995 | -$1.20 M | - | - |
FAQ
- What is Silence Therapeutics annual free cash flow?
- What is the all time high annual FCF for Silence Therapeutics?
- What is Silence Therapeutics annual FCF year-on-year change?
- What is Silence Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Silence Therapeutics?
- What is Silence Therapeutics quarterly FCF year-on-year change?
- What is Silence Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Silence Therapeutics?
- What is Silence Therapeutics TTM FCF year-on-year change?
What is Silence Therapeutics annual free cash flow?
The current annual FCF of SLN is -$49.02 M
What is the all time high annual FCF for Silence Therapeutics?
Silence Therapeutics all-time high annual free cash flow is $7.53 M
What is Silence Therapeutics annual FCF year-on-year change?
Over the past year, SLN annual free cash flow has changed by +$7.81 M (+13.75%)
What is Silence Therapeutics quarterly free cash flow?
The current quarterly FCF of SLN is -$26.13 M
What is the all time high quarterly FCF for Silence Therapeutics?
Silence Therapeutics all-time high quarterly free cash flow is $35.54 M
What is Silence Therapeutics quarterly FCF year-on-year change?
Over the past year, SLN quarterly free cash flow has changed by -$11.97 M (-84.50%)
What is Silence Therapeutics TTM free cash flow?
The current TTM FCF of SLN is -$55.91 M
What is the all time high TTM FCF for Silence Therapeutics?
Silence Therapeutics all-time high TTM free cash flow is $18.85 M
What is Silence Therapeutics TTM FCF year-on-year change?
Over the past year, SLN TTM free cash flow has changed by -$6.89 M (-14.05%)